TY - JOUR
T1 - 17β-estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat
AU - Corasaniti, M. T.
AU - Amantea, D.
AU - Russo, R.
AU - Piccirilli, S.
AU - Leta, A.
AU - Corazzari, M.
AU - Nappi, G.
AU - Bagetta, G.
N1 - Funding Information:
Financial support from FIRB (RBNE01E7YX_005) and ISS (IV AIDS National Programme) is gratefully acknowledged.
PY - 2005/10
Y1 - 2005/10
N2 - The human immunodeficiency virus type 1 (HIV-1) coat glycoprotein gp120 represents a likely contributor to the development of HIV-1 associated dementia (HAD), a neurological syndrome often observed in AIDS patients and characterised by significant neuronal loss in the neocortex. Since recent studies have highlighted that female sex hormones represent potential neuroprotective agents against damage produced by acute and chronic injuries in the adult brain, we have investigated whether estrogens exert protection in a rat model of gp120 neurotoxicity. Our results demonstrate that systemic administration of 17β-estradiol (E 2, 0.02-0.2 mg/kg) significantly reduces apoptotic cell death observed in the neocortex of rat following subchronic i.c.v. administration of gp120 (100 ng/rat/day). Furthermore, both tamoxifen and ICI182,780, two selective antagonists of estrogen receptors (ER) in the brain, reverted the neuroprotective effect of E 2. The molecular mechanism of estrogenic neuroprotection does not appear to involve modulation of the antiapoptotic Bcl-2 or the proapoptotic Bax since we failed to observe changes in the levels of the two proteins in the neocortical tissue after gp120 and/or E 2 treatment. However, we detected increased levels of IL-1β in the neocortex of rats injected with gp120, as early as 6 h after drug administration, and this effect was potentiated following pretreatment with E 2. Taken together, our results demonstrate that E 2 exerts neuroprotection against gp120 neurotoxicity in vivo through a mechanism involving ER activation and, possibly, via modulation of neocortical levels of IL-1β.
AB - The human immunodeficiency virus type 1 (HIV-1) coat glycoprotein gp120 represents a likely contributor to the development of HIV-1 associated dementia (HAD), a neurological syndrome often observed in AIDS patients and characterised by significant neuronal loss in the neocortex. Since recent studies have highlighted that female sex hormones represent potential neuroprotective agents against damage produced by acute and chronic injuries in the adult brain, we have investigated whether estrogens exert protection in a rat model of gp120 neurotoxicity. Our results demonstrate that systemic administration of 17β-estradiol (E 2, 0.02-0.2 mg/kg) significantly reduces apoptotic cell death observed in the neocortex of rat following subchronic i.c.v. administration of gp120 (100 ng/rat/day). Furthermore, both tamoxifen and ICI182,780, two selective antagonists of estrogen receptors (ER) in the brain, reverted the neuroprotective effect of E 2. The molecular mechanism of estrogenic neuroprotection does not appear to involve modulation of the antiapoptotic Bcl-2 or the proapoptotic Bax since we failed to observe changes in the levels of the two proteins in the neocortical tissue after gp120 and/or E 2 treatment. However, we detected increased levels of IL-1β in the neocortex of rats injected with gp120, as early as 6 h after drug administration, and this effect was potentiated following pretreatment with E 2. Taken together, our results demonstrate that E 2 exerts neuroprotection against gp120 neurotoxicity in vivo through a mechanism involving ER activation and, possibly, via modulation of neocortical levels of IL-1β.
KW - 17β-Estradiol (E )
KW - HIV-1 associated dementia (HAD)
KW - gp120
UR - http://www.scopus.com/inward/record.url?scp=26444598059&partnerID=8YFLogxK
U2 - 10.1016/j.neuro.2005.01.019
DO - 10.1016/j.neuro.2005.01.019
M3 - Article
SN - 0161-813X
VL - 26
SP - 893
EP - 903
JO - NeuroToxicology
JF - NeuroToxicology
IS - 5
ER -